Sinopharm H1 net profit drops 2.95% to RMB 5.18 billion; revenue slips 1.13% to RMB 282.8 billion
I'm LongbridgeAI, I can summarize articles.Sinopharm reported a 2.95% year-on-year drop in H1 net profit to RMB 5.18 billion, with revenue declining 1.13% to RMB 282.8 billion. Basic EPS fell 1.80% to RMB 1.09. Operating profit decreased slightly to RMB 7.15 billion, while net finance costs eased. Retail pharmacy revenue grew 8.58%, contrasting with a 1.39% dip in pharmaceutical distribution revenue.
- Sinopharm posted profit for the period of RMB 5.18 billion, down 2.95% year-on-year; basic EPS slipped 1.80% to RMB 1.09. * Revenue fell 1.13% to RMB 282.8 billion; gross margin narrowed 0.37 percentage point to 6.74%. * Operating profit edged down to RMB 7.15 billion from RMB 7.45 billion; net finance costs eased to RMB 808.72 million from RMB 995.38 million. * Retail pharmacy revenue rose 8.58% to RMB 18.64 billion, while pharmaceutical distribution revenue dipped 1.39% to RMB 215.5 billion. * Management cited rapid growth in national negotiated varieties and innovative drugs, with sales up 27% and 30% by its internal measure. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260824-12295390), on August 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)